Category: Transactions

Guangzhou, China, March. 1, 2021  — TMFOX VENTURE PARTNERS, a boutique investment bank and venture investor for global healthcare announces that it has entered into an exclusive financial advisory agreement with Guangzhou Rongli Bio-Medical Co.,ltd for its estimated 6 million USD fundraising.  

Commenting on the agreement, Dr.Yong Yang, Founder of Rongli, said, “We are delighted to work with TMFOX toward these great objectives With the joint efforts of our two companies, we are confident tremendous success will be achieved and significant benefits will be delivered to people who love the beauty.”

About Guangzhou Rongli

Guangzhou Rongli Biotechnology Co., Ltd. has a construction area of ​​38 acres and a factory production area of ​​11,000 square meters. It has a second-class medical device business license, a “machine name” product production license, and a disinfection product production license. The product is safe and effective Sex is guaranteed.

About TMFOX VENTURE PARTNERS

TMFOX focuses on the evolution of global Healthcare and is committed to empowering its clients with cross-border funding, business development, and risk management. TMFOX offers holistic solutions that help clients grow competitive in this constantly evolving market. Founded in 2009 in Shenzhen in China by Andy Yu, the boutique investment bank has operations in 6 cities across China and 3 international cities such as Vancouver, Seattle, and Boston in North American.

Shenzhen, China, Feb. 20, 2021  — TMFOX VENTURE PARTNERS, a boutique investment bank and venture investor for global healthcare announces that it has entered into an exclusive financial advisory agreement with Balanlife Dialysis Chain (Shenzhen) Co.,ltd for its capital operation including merger and acquisition of specialized chronic disease hospitals, dialysis chain clinics across mainland China, estimated 20 million USD fundraising, and preparation of initial public listing.  

Commenting on the agreement, Wei Liu, Founder of Balanlife, said, “We are delighted to work with TMFOX toward these great objectives With the joint efforts of our two companies, we are confident tremendous success will be achieved and significant benefits will be delivered to patients across China.”

About Balanlife Dialysis

Founded in 2009, Balanlife Dialysis Chain (Shenzhen) Co., Ltd. is a well-known national brand focusing on a chain clinic business for dialysis, with clinics in Guangzhou, Shaoguan, Yunfu, Zhaoqing, Jiangmen, Jieyang, Shantou, Fujian, Hubei, and other places. For more information, please visit http://www.balanlife.com/

About TMFOX VENTURE PARTNERS

TMFOX focuses on the evolution of global Healthcare and is committed to empowering its clients with cross-border funding, business development, and risk management. TMFOX offers holistic solutions that help clients grow competitive in this constantly evolving market. Founded in 2009 in Shenzhen in China by Andy Yu, the boutique investment bank has operations in 6 cities across China and 3 international cities such as Vancouver, Seattle, and Boston in North American.

Vancouver, Canada Feb 26, 2021.  — TMFOX VENTURE PARTNERS, a boutique investment banker and venture investor for global healthcare reached an agreement with saNOtize Research and Development Corp, a Vancouver-based bio-tech company for the endeavor of technology license and new market development partnership.

saNOtize utilizes the unique antimicrobial and immunomodulating properties of Nitric Oxide to treat diseases of the respiratory system and the skin. The company’s platform technology, NORS^TM, can treat a variety of topical infections. From sinusitis via nasal lavage and the flu via nasal spray, to acne via topical gel. Dr. Gilly Regev, PhD and Dr. Chris Miller, PhD, BA, RT are co-founders of SaNOtize.  Dr. Regev and Dr. Miller are among a small group of people who are experts at using nitric oxide therapeutically.

SaNOtize is also working diligently with Health Canada and the FDA to obtain approval for the emergency release of preventative treatment for healthcare workers and high-risk individuals exposed to SARS-CoV-2.

Commenting on the agreement, Andy Yu, President of TMFOX, said, “In considering the getting worse infection disease and strong demand for skincare, We believe the Asia market,especially China market, has the great potential to benefit back the long time hard-working on R&D. ”

About TMFOX VENTURE PARTNERS

TMFOX focuses on the evolution of global Healthcare and is committed to empowering its clients with cross-border funding, business development, and risk management. TMFOX offers holistic solutions that help clients grow competitive in this constantly evolving market. Founded in 2009 in Shenzhen in China by Andy Yu, the boutique investment bank has operations in 6 cities across China and 3 international cities such as Vancouver, Seattle, and Boston in North American.

May 28, 2020 11:00 ET | Source: Genome British Columbia

VANCOUVER, British Columbia, May 28, 2020 (GLOBE NEWSWIRE) — Genome BC is pleased to announce $1 million in funding to Sonic Incytes Medical Corp., completing the company’s seed financing round of over CDN$3.5 million supported by institutional investors, angel funds and private individuals. Vancouver based Sonic Incytes is developing a breakthrough, point of care ultrasound solution for assessing and managing chronic liver disease – an emerging global health crisis, affecting one in four persons worldwide.  

In addition to Genome BC’s investment, Sonic Incytes also raised over $2.5M in seed financing from institutional investors Small World Group, Think Top Investments and Sunhope Venture Capital, as well as angel investors World Changing Ventures, TMFOX, UBC Seed Fund and E-Fund.

Fatty liver disease is the fastest growing and largest segment of chronic liver disease, driven largely by the increasing prevalence of diabetes and obesity. The continued growth in patients and emergence of potential new therapies creates an urgent need for a cost-effective, quick, and accurate diagnostic solution to assess and manage the progression and treatment of this disease. 

“We are pleased to provide Sonic Incytes with $1 million in capital through our Industry Innovation (I²) Fund,” says Dr. Tony Brooks, Chief Financial Officer and Vice President, Entrepreneurship  & Commercialization at Genome BC. “Our investment, alongside funding from other investors, will help Sonic Incytes commercialize this innovative solution and make a significant difference in the management of liver disease and improve overall health and wellness.”

“This financing will go a long way in helping us redefine the standard of care in quantifying fatty liver disease. Physicians will soon be able to accurately diagnose liver disease with a solution comparable to MRI,” said George Aliphtiras, CEO, Sonic Incytes Medical Corp. “Access to a point of care diagnostic solution that replaces biopsy and MRI is an urgent unmet need for effective patient management, and we are ideally positioned to address this emerging health crisis.”

Currently definitive diagnostic tools for fatty liver disease are limited to biopsy and MRI, which are expensive, invasive and time-consuming. Sonic Incyte’s portable, handheld solution uses technology similar to MRI elastography, quantifying liver disease using 3D tissue sampling. It is a point of care solution that provides consistently accurate results, and a clear picture of liver health in real time, so that physicians can be confident in their diagnosis, treatment and care. In addition, the entire procedure takes about five minutes in a doctor’s office, contributing to a quick, safe and comfortable patient experience.

About the Industry Innovation Fund:
Genome BC has invested in Sonic Incytes through its Industry Innovation (I²) program. The I² Fund provides commercialization support for companies developing innovative life science technologies that address biological challenges in key economic sectors in BC: Agriculture, Energy and Mining, Environment, Fisheries and Aquaculture, Forestry, and Human Health. The I² Fund also supports digital health and other technologies that further move precision medicine into clinical practice. I² funding is repayable and is allocated to promising technologies (products, processes or services) at the early stages of commercial development. The Fund aims to provide risk capital that is concurrently matched by other public or private funding sources.

About Genome British Columbia:
Genome British Columbia leads genomics innovation on Canada’s West Coast and facilitates the integration of genomics into society. A recognized catalyst for government and industry, Genome BC invests in research, entrepreneurship and commercialization in life sciences to address challenges in key sectors such as health, forestry, fisheries and aquaculture, agrifood, energy, mining and environment. Genome BC partners with many national and international public and private funding organizations to drive BC’s bioeconomy. www.genomebc.ca

About Sonic Incytes Medical Corp.:
Recognizing the rise of fatty liver disease, Sonic Incytes has a mission to reduce the disease by enabling routine assessment and management of liver health. It plans to enter the market with its breakthrough, point of care ultrasound solution at the end of 2020. In April 2020, Sonic Incytes was recognized as a Ready to Rocket Life Science company for its innovative technology and potential for growth. Founded in 2017, Sonic Incytes is a medical device company headquartered in Vancouver, British Columbia, Canada. www.sonicincytes.com

About TMFOX VENTURE PARTNERS

TMFOX focuses on the evolution of global Healthcare and is committed to empowering its clients with cross-border funding, business development, and risk management. TMFOX offers holistic solutions that help clients grow competitive in this constantly evolving market. Founded in 2009 in Shenzhen in China by Andy Yu, the boutique investment bank has operations in 6 cities across China and 3 international cities such as Vancouver, Seattle, and Boston in North American.

Nov.5, 2019 – UBC, Vancouver, Canada

TMFOX VENTURE PARTNERS is pleased to announce an Advisory Agreement to Orbitless Drives Inc. Orbitless Drives Inc was formed out of an idea about optimization. “How to make a robotic system more cost effective to make and get rid of that annoying ring gear”, was the thesis that inventor and founder Dr Leo Stocco had. After doing his PhD in Electromechanical Optimization and spending a few years at a Robotics company focused on Robotic Surgical systems, Leo gave himself an optimization challenge. After doing a few years of basement lab engineering… the result is the Orbitless Drive platform. Patented in US, China and Europe, Orbitless is poised to become a new standard in Gear design, alongside the existing technologies like planetary, parallel axis and strainwave (harmonic) drive technologies. With this Advisory Agreement, TMFOX VENTURE PARTNERS servers a member of Advisory Board and oversees overall strategy of accessing into China market, including partnership building, deal structure , investments with viable funds.

With this Advisory Agreement, TMFOX VENTURE PARTNERS servers a member of Advisory Board and oversees overall strategy of accessing into China market, including market reserach, product/business model design, clinic trial and regulatory approval, deal structure , investments with viable funds(RMB Fund and USD FUND).